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Abstract
The ability to regulate inflammatory pathways and host defense mechanisms is critical for 
maintaining homeostasis and responding to infections and tissue injury. While unbalanced 
inflammation is detrimental to the host; inadequate inflammation might not provide effective 
signals required to eliminate pathogens. On the other hand, aberrant inflammation could result in 
organ damage and impair host defense. The lipid mediator leukotriene B4 (LTB4) is a potent 
neutrophil chemoattractant and recently, its role as a dominant molecule that amplifies many arms 
of phagocyte antimicrobial effector function has been unveiled. However, excessive LTB4 
production contributes to disease severity in chronic inflammatory diseases such as diabetes and 
arthritis, which could potentially be involved in poor host defense in these groups of patients. In 
this review we discuss the cellular and molecular programs elicited during LTB4 production and 
actions on innate immunity host defense mechanisms as well as potential therapeutic strategies to 
improve host defense.
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1. Introduction
The ability of innate immune cells to properly recognize, respond, and eliminate invading 
pathogens is a requisite for host survival. Microbial infections quickly elicit an inflammatory 
program that induces the recruitment of phagocytes, such as macrophages, monocytes and 
neutrophils. These newly migrated cells further enhance the production of pro-inflammatory 
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mediators such as cytokines, chemokines, growth factors, and bioactive lipids in the 
inflammatory milieu. After exposure to pathogens, sentinel cells such as epithelial cells and 
phagocytes (tissue resident macrophages and dendritic cells) detect pathogen associated 
molecular patterns (PAMPs) via binding to pattern recognition receptors (PRRs). Activation 
of PRRs such as Toll like receptors (TLRs) trigger the signaling programs that culminate in 
the generation of inflammatory cytokines and lipid mediators to provide signals essential to 
the recruitment of cells involved in the control of pathogens. The bioactive lipid mediator 
leukotriene B4 (LTB4) is produced primarily by neutrophils and macrophages and signals 
through its high or low affinity receptor B leukotriene receptor (BLT) 1 or 2, respectively, to 
enhance phagocyte antimicrobial effector functions. However, aberrant levels of LTB4 can 
be detrimental to host response and may be pathogenic in inflammatory diseases.
Effective inflammatory programs induced during infections can be compromised by 
underlying health conditions [1]. Although inflammation is important for coordinating 
immune responses during infection, excessive inflammatory responses can be destructive. 
Patients with chronic inflammatory diseases, such as diabetes, arthritis, and atherosclerosis 
have dysregulated inflammatory response functions and are more prone to infections [2–4].
This review covers the current understanding of the role of LTB4 and BLT1 on host defense 
mechanisms and how modulating the LTB4/BLT1 pathway can be therapeutically targeted to 
respectively amplify or inhibit host defense in settings of immunodeficiency or aberrant 
inflammation.
2. LT synthesis and receptors
2.1 LT synthesis
LTs are part of a large family of lipids termed eicosanoids that are derived from the Greek 
word “eicosa” since eicosanoids are made of 20 carbon atoms called eicosatetraenoïc acid. 
The synthesis of LTs involves several rate-limiting steps that comprise activation of 
phospholipase A2 (PLA2) and arachidonic acid (AA) release from phospholipids in the 
cellular membranes. Activation of 5-LO in concert with the 5-LO activation protein (FLAP) 
metabolizes AA to LTA4, which is converted to LTB4 by LTA4 hydrolase. LTA4 could 
alternatively be modified with glutathione by LTC4 synthase to form LTC4. Further 
modifications of LTC4 give rise to LTD4 and LTE4. Since LTC4, D4, and E4 contain a 
cysteine, they are known as the cysteinyl leukotrienes (CysLTs). Even though CysLTs exert 
stimulatory effects on macrophages and neutrophils, this review will focus primarily on 
LTB4 actions. The main cellular sources of LTB4 in both murine and humans are 
granulocytes, monocytes, and macrophages (Table 1) [5]. However, murine (RAW264.7 and 
J774) and human (THP1 and U937) macrophage cell lines express low levels of 5-LO and 
produce barely detectable levels of LTB4 [6]. Non-immune cells are also capable to produce 
LTB4. Some cell types have been reported to express some but not all of the LT-synthesis 
enzymes, which renders these cells incapable of synthesizing leukotrienes independently. 
However, these cells may be able to contribute to the synthesis of LTs in a process known as 
transcellular biosynthesis [7]. An example of transcellular biosynthesis of LTB4 is between 
neutrophils-erythrocytes, and keratinocytes and endothelial cells [8–12]. Table 1 lists the 
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cellular expression of leukotriene synthesis enzymes. Although this topic is of interest, a 
more comprehensive review can be found at [13].
5-LO activity is dependent on various signals including calcium release and 
phosphorylation, which control the catalytic site and the translocation of 5-LO within the 
cell. In a resting cell, 5-LO location varies depending on the cell type [14]. In neutrophils 
and peritoneal macrophages, 5-LO is located in the cytosol whereas in alveolar macrophages 
and Langerhans cells, 5-LO is located within in the nucleus [15–17]. Upon cell activation, 
increased intracellular calcium levels induce 5-LO to translocate to the perinuclear or 
plasmatic membrane where it can metabolize AA into LTA4 [18]. 5-LO activity is triggered 
by various stimuli such as pathogens, cytokines, and immune complexes [19]. During 
infection, pathogens have limited abilities to increase intracellular calcium levels and 
therefore are poor 5-LO activators alone. However, treating infected cells with a calcium 
ionophore or opsonized zymosan particles are able to greatly enhance LT synthesis [20, 21]. 
Table 2 lists the relative levels of LTB4 produced in response to various stimuli. The 
molecular mechanisms that regulate 5-lipoxygenase activation are reviewed here [22, 23].
2.2 LTB4 receptors
There are two G protein coupled receptors (GPCRs) for LTB4, BLT1 and BLT2. BLT1 is a 
high-affinity receptor and BLT2 is a low-affinity receptor. Since other fatty acid metabolites 
besides LTB4 are able to activate BLT2, the effects of BLT2 signaling are not limited strictly 
to LTB4 effects [24]. Distribution of BLT1 and BLT2 on cells and tissues vary between 
mouse and human [24]. On human cells, BLT1 expression is limited to leukocytes (Table 1) 
and BLT2 is ubiquitously found on many cell types. On mouse cells, BLT1 expression is 
detected on leukocytes and BLT2 is found on intestinal epithelium and keratinocytes [24, 
25]. BLT1 can be coupled to Gαi or Gαq that culminate to decrease cyclic AMP (cAMP) 
levels and increase intracellular calcium levels, respectively [26]. We have previously shown 
that BLT1 utilizes mainly Gαi to enhance antimicrobial effector functions in alveolar 
macrophages [26]. Figure 1 demonstrates a schematic of LTB4/BLT1-induced effector 
functions in innate immune cells. The low affinity receptor BLT2 is also expressed in 
phagocytes, but its role in host defense is poorly studied. Previously, we have shown 
blocking BLT2 does not influence phagocytosis and bacterial killing in alveolar 
macrophages [27]. However, BLT2 might be a relevant receptor for other antimicrobial 
effector functions in different organs [24]. Recently, Zhang and Brown have shown that in 
the absence of BLT1, BLT2 enhances macrophage Borrelia burgdorferi phagocytosis. It 
remains to be determined whether BLT2 amplifies neutrophil chemotaxis to the site of 
infection and whether BLT2 controls antimicrobial peptide production in the skin or in the 
gut. However, BLT2 regulation and actions are out of the scope of this review.
3. Effects of LTB4 on host defense mechanisms
3.1 Migration and chemotaxis
Neutrophils are the first cells recruited to the site of infection or injury. There are various 
steps involved in successful recruitment of neutrophils: rolling, adhesion, and 
transendothelial migration [28]. LTB4 is well known for its role as a neutrophil 
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chemoattractant from distant sites to the site of inflammation [29–31]. Also, LTB4 
participates with chemokine gradients to further enhance neutrophil chemotaxis towards 
other chemoattractants such as fMLP, C5a, and heme [32–34]. Neutrophils from mice 
lacking BLT1 are not able to swarm and cluster to a focal damage site. BLT1−/− neutrophils 
have smaller neutrophil clusters than wild type neutrophils [35], demonstrating the 
importance of LTB4/BLT1 signaling in neutrophil accumulation. Additionally, neutrophil 
recruitment is not unidirectional. Reverse transendothelial migration has been reported 
where neutrophils reenter the blood stream after migration to the site of infection or injury 
[36]. In a model of ischemia-reperfusion injury, LTB4 and neutrophil elastase compose an 
important axis that drives reverse transendothelial migration. Neutrophils that reenter the 
vasculature are able to migrate to secondary organs and have the potential to cause injury 
[37].
3.2 Phagocytosis
We, and others, have shown that LTB4/BLT1 signaling amplifies the actions of different 
signaling components required for ingestion of particles. The first demonstration that LTB4 
enhances phagocytosis was shown by Wirth et al using a model of Trypanosoma cruzi 
infection [38]. After this, Dr. Peters-Golden’s group pioneered in demonstrating the role of 
endogenous LTs in amplifying phagocytosis of antibody-opsonized targets [39, 40]. Both 
genetic and pharmacologic blockage of LTB4/BLT1 actions greatly reduces ingestion of a 
myriad of pathogens, including both gram-positive bacteria (Streptococcus pneumoniae) 
[27], gram-negative bacteria (Klebsiella pneumoniae [41]), fungi (Histoplasma capsulatum 
[42, 43], Candida albicans [44], and Paracoccidioides braziliensis [45]), and parasites 
(Leishmania braziliensis [46], L. amazonensis [47], and T. cruzi [38, 48]).
In addition to this extensive list of pathogens, the molecular mechanisms involved in LTB4-
mediated amplification of phagocytosis have been studied. BLT1 signaling enhances 
activation of Syk, a protein tyrosine kinase, important for FcγR-mediated phagocytosis [26, 
49]. When macrophages are challenged with IgG-opsonized targets, LTB4 enhances 
phagocytosis of IgG-RBC in an FcγR1-dependent manner. This enhancement is attributed to 
the association of BLT1 with lipid raft formation and heightened signaling capabilities [50]. 
Furthermore, LTB4 amplifies phagocytosis by increasing phosphorylation of kinases 
involved in the formation of a phagocytic cup, such as PKC-α, PKC-δ, PI3K, and ERK1/2 
[51, 52]. However, the hierarchical role of these kinases in amplifying phagocytosis remains 
to be determined. Molecular studies regarding the signaling programs involved in the 
phagocytosis of nonopsonized pathogens are scarcer than opsonized targets. It has been 
shown that LTB4 enhances C. albicans phagocytosis via activation of GαI-mediated PKC-δ 
and PI3K activation culminating in F-actin polymerization [53]. LT enhancement of yeast 
phagocytosis involves the activation of PKC and PI3K, with subsequent activation of LIM 
Kinase, decreased cofilin-1 activation, and ultimately, F-actin assembly [53]. Furthermore, 
LTB4 enhances phagocytosis of fungi by increasing the expression of dectin-1, a main 
phagocytic receptor detecting fungal pathogens [42]. LTB4-mediated dectin-1 expression is 
dependent on GM-CSF production and activation of the transcription factor PU.1 [44].
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3.3 Pathogen killing mechanisms
We, and others, have extensively shown that LTB4 is a potent neutrophil activator [41, 54–
56]. 5-LO−/− neutrophils or neutrophils treated with leukotriene synthesis inhibitors have 
significantly lower ingestion of serum-opsonized K. pneumoniae [41]. Exogenous LTB4 
treatment restores phagocytic capabilities in 5-LO deficient neutrophils [40, 45]. After 
phagocytosis, neutrophils kill pathogens by producing toxic components within granules that 
are released in a process known as neutrophil degranulation [57]. When human neutrophils 
are infected in vitro with the parasite L. amazonensis, endogenous and exogenous LTB4 
promotes neutrophil degranulation [47]. Also, LTB4 induces release of myeloperoxidase 
[55] and elastase in neutrophils [37, 58]. LTB4 treatment of mice infected with influenza 
virus induced production of antimicrobial peptides β-defensin 3 and Cramp [59], the mouse 
ortholog of human cathelicidin LL-37. In human neutrophils, LTB4 induces the production 
of LL-37 in a dose-dependent manner [56].
Reactive oxygen and nitrogen species (ROS and RNS) production is another important 
antimicrobial effector function that phagocytes use to kill pathogens. LTB4 enhances the 
production of NADPH oxidase-dependent ROS generation [54, 60]. We, and others, have 
shown that LTB4 enhances ROS-dependent NADPH oxidase activation via phosphorylation 
of the cytosolic subunit p47phox. This activation is dependent on PKC-δ [54], ERK-1/2 and 
PI3K activation [61]. LTB4 is part of a positive-feedback loop in human neutrophils infected 
with L. amazonensis, which is important to kill parasites [47]. Similar to neutrophils, 
macrophages produce a variety of different microbicidal molecules such as ROS, RNS, 
antimicrobial peptides, and indoleamine deoxygenase (IDO). LTB4 is known to enhance the 
generation of most microbidicidal molecules mentioned above. LTB4-mediated ROS 
production in macrophages is dependent on PKC-δ-mediated p47phox and p40phox 
phosphorylation and membrane translocation in alveolar macrophages challenged with 
opsonized K. pneumoniae [52]. Furthermore, we also showed that aerosolized LTB4 
increases p47phox expression and membrane translocation during Streptococcus 
pneumoniae lung infection [62]. Additionally, our unpublished results show that 
macrophages from BLT1−/− mice have impaired phagocytosis and killing of gram-positive 
methicillin-resistant Staphylococcus aureus (MRSA), which correlates with diminished ROS 
production in macrophages from the BLT1 deficient mice.
LTB4-dependent RNS production is dependent on NFκB and STAT1 activation [46]. LTB4 
treatment further enhances the production of nitric oxide (NO) in murine macrophages, 
which improves killing of different pathogens such as L. amazonensis and T. cruzi [52, 63]. 
It remains to be determined whether LTB4 enhances noncanonical microbicidal effectors in 
macrophages such as antimicrobial peptides, tryptophan depletion (via IDO activation), 
GTPases, and transferrin receptor activation.
3.4 PRR activation and cytokine generation
TLRs are known to detect both PAMPs and danger associated molecular patterns (DAMPs). 
There are 11 TLRs in human and 13 in mouse. TLRs can be found on the cell surface of 
immune cells or in endosomes located within cells. The role of LTB4 in TLR activation has 
been suggested [64–66]. TLR signaling induces pro-inflammatory cytokine responses [67, 
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68]. TLR2 is a cell surface receptor that senses peptidoglycan molecules commonly found 
on gram-positive bacteria and TLR9 is an endosomal receptor that detects DNA [67, 68]. 
LTB4 stimulation upregulates the expression of TLR2 and TLR9 in human neutrophils [69]. 
Enhanced expression of TLRs could allow for neutrophils to better sense various pathogens 
and induce a stronger signaling cascade, which allows for a more potent immune response. 
Furthermore, LTB4 is also known to amplify the actions of different PRRs. TLR activation is 
dependent on different adaptors such as myeloid differentiation factor 88 (MyD88) and TIR-
domain-containing adapter-inducing interferon-β (TRIF). Most TLRs except TLR3 utilize 
MyD88, and only TLR3 and TLR4 utilize TRIF. MyD88 activation is followed by 
phosphorylation of downstream components such as IRAKs and TAK-1. LTB4 enhances 
MyD88 expression and MyD88-dependent activation of NFκB, which are able to intensify 
the signaling potential of TLRs and other PPRs [64]. The mechanisms involved in LTB4-
enhanced MyD88 expression relies on enhancing the activation of STAT1, the main 
transcription factor responsible for MyD88 expression [70]. BLT1 activation leads to mRNA 
degradation of suppressor of cytokine signaling 1 (SOCS1), the major STAT1 negative 
regulator, which contributes to enhanced MyD88 expression and subsequent enhancement of 
TLR-mediated macrophage activation [64]. Furthermore, it has been shown that LTB4 
amplifies the phosphorylation of IRAK and TAK-1 in human neutrophils [66]. In all 
circumstances, through TLR and PRR activation, LTB4 amplifies the induction of cytokine 
production. LTB4/BLT1 enhancement of inflammatory cytokine production has been 
extensively studied. LTB4 is known to induce the cytokines GM-CSF, TNF-α, IL-6 and 
IL-1β and the chemokines KC, MCP-1, CXCL1, and CXCL2 that are thought to enhance 
inflammatory responses [71, 72].
Another layer of immune regulation induced by LTB4 is the expression of microRNAs 
(small ~22 nucleotides in length) that inhibits mRNA degradation or translation. We have 
shown that 5-LO deficient macrophages exhibit a decreased expression of a specific set of 
inflammatory microRNAs (inflammatory regulon). Among these microRNAs, we detected 
decreased levels of miR-155, miR-125b, and miR-146b in LT-deficient cells [73]. We have 
shown that these microRNAs specifically bind to SOCS1 3′UTR, restrict SOCS1 expression 
and enhance MyD88 expression [64]. Therefore, LTB4/BLT1 axis provides very potent and 
pleiotropic signals by decreasing microRNA expression and allowing inflammatory 
programs to be elicited in macrophages.
4. Aberrant LTB4 is detrimental to host defense
Chronic inflammatory morbidities are accompanied by aberrant LTB4 production that is 
thought to negatively influence disease pathogenesis. Among the diseases that LTB4 plays a 
detrimental role include type 1 and type 2 diabetes, arthritis, and atherosclerosis [74–80]. 
The bad reputation of LTB4 comes from its capacity to maintain inflammatory programs in 
monocytes/macrophages and prolonging neutrophil recruitment to the inflammatory foci. 
LTB4/BLT1 blockade is expected to dampen inflammatory responses and restore tissue 
homeostasis during chronic inflammation.
Besides increased production of LTB4, chronic inflammatory diseases are often associated 
with co-morbidities, including the major threat of increased susceptibility to infections. 
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Although LTB4 plays a beneficial role in promoting pathogen clearance, the counterintuitive 
effect of LTB4 in chronic inflammatory diseases could be explained by the overwhelming 
inflammatory response and lack of proper phagocyte response to pathogens. Abundant LTB4 
production and detrimental host defense responses have been associated in a zebrafish model 
of Mycobacterium marinum infection. The authors showed that LTA4 hydrolase (LTA4H), 
the enzyme that converts LTA4 to LTB4, is an important susceptibility factor involved in 
Mycobacterium infection. Zebrafish expressing hyperactive LTA4H are hypersusceptible to 
M. marinum infection [81]. Additionally, overexpression of LTA4H produces high levels of 
LTB4 that drive aberrant TNFα production and uncontrolled mycobacterial infections [82]. 
Furthermore, zebrafish expressing the enzyme that inactivates LTB4, leukotriene B4 
dehydrogenase/prostaglandin reductase 1 (LTB4DH/PTGR1), exhibit lower bacterial 
numbers than WT zebrafish. The susceptibility to infection of LTB4DH mutant animals can 
be reversed with BLT1 antagonism, further implicating LTB4 as detrimental to host defense 
during Mycobacteria infection in zebrafish [83].
Exaggerated LTB4 is also detrimental to systemic infection (sepsis). 5-LO−/− mice or 
pharmacological inhibition of BLT1 actions protect mice during cecum ligation and 
puncture (CLP). 5-LO−/− and WT mice treated with a LT synthesis inhibitor have drastically 
lower levels of neutrophil infiltrates and lower levels of inflammatory cytokines such as 
IL-1β [84]. During CLP-induced sepsis, treatment with the BLT1 antagonist U-75302 
decreases lung injury [85] as evidenced by decreased neutrophil recruitment. 
Therapeutically regulating 5-LO products or blocking BLT1 during or after sepsis may help 
prevent organ injury. Aberrant LTB4 production also renders diabetic mice more susceptible 
to sepsis than nondiabetic animals. We have shown that increased LTB4 drives MyD88 
expression and mediates chronic systemic inflammation in diabetic mice. Diabetic BLT1−/− 
mice are protected from sepsis, which correlates with lower inflammatory cytokine 
production and decreased MyD88 expression.
Given the pleiotropic effects of LTB4 on amplifying the actions of immune receptors by 
influencing intracellular programs and gene transcription in macrophage and neutrophil 
activation [86], exaggerated LTB4 levels could be influencing both the actions of PRR (via 
increased expression of MyD88 [64, 73]), cytokine (GMCSF,TNF-a and IL1b [44, 64, 87]), 
and phagocytic receptors (FcRs and dectin receptor [50, 52]) and transcription factors 
(NFkB, AP1 and PU.1 [44, 64, 73]) to elicit inflammatory programs and cause organ injury 
and poor host defense.
The mechanisms involved in aberrant LTB4 production and poor systemic and localized host 
defense remains to be determined. However, preliminary data from our laboratory suggest 
that local uncontrolled LTB4 production drives a robust production of chemokines and 
cytokines along with overwhelming neutrophil migration to the site of infection that releases 
inflammatory mediators that cause tissue damage. Furthermore, exaggerated BLT1 
activation seems to impair clearance of dead cells by controlling the expression of don’t eat 
me signals, such as CD47 [88]. When apoptotic cells are not cleared properly, these cells 
become necrotic and secrets many danger associated molecular patterns (DAMPs) [89, 90]. 
DAMP secretion might lead to LTB4 production which could be part of an amplification 
loop involved in chronic inflammation and lack of bacterial clearance observed in diabetes. 
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Whether these molecular events are involved in enhanced susceptibility to skin infections in 
people with diabetes remains to be determined and are an active research program in our 
laboratory.
5. Manipulating LTB4 levels/actions as a therapeutic potential to control 
host defense
5.1 Enhance LTB4 effects
There are many potential advantages to using LTB4 in immunotherapeutic protocols, which 
include: (i) generation of proteins is relatively expensive, time consuming and subject to 
contamination with products of the vectors used to generate the protein, while lipids can be 
produced quickly and with a high degree of purity; (ii) because lipids exhibit are known to 
have a short half-life, it offers flexibility and precision in controlling localized or systemic 
actions; (iii) LTB4 is safe to be administered to the human lung in vivo; and (iv) LTB4 could 
amplify initial antimicrobial responses by enhancing pathogen recognition and phagocytosis, 
release of NADPH oxidase-derived ROS, and pro-inflammatory responses through MyD88 
expression and activation of inflammatory transcription factors.
Treatment protocols employing exogenous LTB4 can be greatly beneficial to patients known 
to exhibit attenuated LT synthesis such as in malnutrition [91], cigarette smoking [92], 
vitamin D deficiency [93], HIV infection [94], and bone marrow transplantation [95]. These 
patients are more susceptible to infection. Therefore, adding back LTB4 to immunodeficient 
patients could potentially restore phagocyte response and favor appropriate host defense.
We, and others, have starting paving the way to establish treatment protocols to determine 
the therapeutic effects of LTB4 in host defense. Exogenous LTB4 treatment is able to boost 
effector functions in wild type mice. In a model of Streptococcus pneumoniae lung 
infections, aerosolized LTB4 treatment was effective in restoring host defense mechanisms 
in 5-LO−/− mice and enhancing effector functions in wild type mice [62]. Intravenous 
injection of LTB4 in macaques enhances plasma levels of the antimicrobial peptide α-
defensins. Plasma from the treated macaques can neutralize pathogens ex vivo [96]. LTB4 
treatment during influenza virus infection reduces viral titers compared to untreated mice 
[59]. The reduction in viral titers correlates with enhanced levels of the cathelicidin-related 
antimicrobial peptide (Cramp). Neutrophils are a major source of Cramp so when mice are 
depleted of neutrophils, exogenous LTB4 treatment during influenza infection is unable to 
control viral load [59].
A potential pitfall is the fact that LTB4 could lead to overwhelming recruitment of 
neutrophils, which may contribute to tissue injury. Also, the stability and safety of LTB4 in 
vivo is a concern, but its been shown that bronchoscopy instillation of LTB4 into the airways 
of normal human subjects elicited a marked influx of neutrophils. Its inhalation proved to be 
well tolerated and caused no adverse effects on blood pressure, pulmonary function, or 
bronchial responsiveness [97].
The importance of LTB4 during infections is clear and exogenous treatment with LTB4 may 
be a potential therapeutic strategy. However, high LTB4 levels during some infections or in 
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chronic inflammatory diseases may need to be blunted to limit inflammation and alternative 
therapeutic strategies to prevent infection-mediated organ injury are necessary.
5.2 Preventing exaggerated LTB4 actions in host defense
Overwhelming production of inflammatory mediators and reactive oxygen species are 
known to be detrimental to host defense in different models of infection [98–101]. 
Therapeutic strategies to block the actions of inflammatory mediators could also restore 
protective host defense. In our laboratory, we are focusing our efforts in understanding 
whether preventing BLT1 and/or BLT2 actions could be an important tool to control 
exaggerated inflammatory response and poor host defense in people with preexisting chronic 
inflammatory conditions, such as diabetes, obesity, asthma, rheumatoid arthritis and elderly. 
It is known that people with diabetes are more susceptible to numerous infections, including 
systemic, respiratory, and skin infections [2–4]. Indeed, both innate and adaptive immune 
cells from diabetics have impaired functions including poor phagocytosis and killing of 
pathogens [102, 103]. We have shown that macrophages from diabetic mice produce higher 
levels of LTB4 than from control mice even under basal conditions [65]. Although seemingly 
counterintuitive, the mechanism by which people with diabetes are more susceptible to 
infections may operate in a similar manner to other infections where high levels of LTB4 is 
detrimental to host defense [81, 83]. We detected higher levels of LTB4 in the serum of 
septic and diabetic mice when compared to the levels of LTB4 detected in septic and 
nondiabetic mice. Diabetic mice treated with the 5-LO inhibitor AA-861 greatly improve 
survival during sepsis. The increase in survival correlates with reduction in IL-1β [65]. 
Since LTB4 is able to enhance IL-1β levels through inflammasome activation [104] and that 
LTB4/BLT1 signaling enhances MyD88 and NFκB activities [64], it is possible that LTB4 
synthesis inhibition or actions prevents overwhelming Toll-interleukin receptors, such as 
IL1R, IL18R1 and TLR actions prevents organ damage. Therefore, a potential therapeutic 
opportunity to treat sepsis in diabetic mice could rely on preventing overwhelming 
inflammation with a BLT1 antagonist along with antibiotics to prevent bacterial growth.
Our unpublished data also show the detrimental role of aberrant LTB4 on host defense in 
diabetic mice in a model of local infection. Diabetic mice are more susceptible to MRSA 
skin infection than nondiabetic mice. Diabetic mice infected with MRSA have increased 
LTB4 production in the skin, which correlates with uncontrolled production of inflammatory 
mediators and neutrophil migration. Topical treatment with a BLT1 antagonist improves skin 
host defense in diabetic mice, as evidenced by decreased lesion size and bacterial numbers 
(data not shown).
6. Conclusion
LTB4 is a homeostatic determinant for optimal host defense in healthy individuals by driving 
pleiotropic actions on phagocytes that include phagocyte chemotaxis, amplifying 
macrophage/neutrophil antimicrobial effector functions, and production of cytokines. 
However, during chronic diseases characterized by aberrant LTB4 levels, excessive LTB4 
could be responsible for impaired host defense mechanisms. In the era of antibiotic-resistant 
pathogens, new therapeutic strategies are critically needed. Modulating levels of LTB4 to 
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either enhance or limit immune responses as appropriate is a potential strategy that could be 
used as a single agent or in combination with antibiotics for an added benefit. There is a 
great need of further research in areas of inflammation regulation under homeostatic 
conditions and during infections as well as understanding how chronic illnesses alter these 
immune responses. This will allow for the development of customized immunomodulatory 
therapies.
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Abbreviations
LT leukotriene
PAMP pathogen associated molecular patterns
PRR pattern recognition receptor
AA arachidonic acid
LO lipoxygenase
cPLA2 cytosolic phospholipase A2
FLAP 5-lipoxygenase-activating protein
cysLT cysteinyl LT
BLT B leukotriene receptor
cAMP cyclic adenosine monophosphate
PKC protein kinase C
ERK extracellular signal-related kinase
PI3K phosphoinositide 3-kinase
NFκB nuclear factor kappa B
AP1 activator protein 1
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Highlights
• LTB4 triggers signaling programs necessary for effective clearance of 
pathogens
• LTB4/BLT1 signaling enhances innate and adaptive immune receptor effector 
functions
• LTB4 can therapeutically boost host defense in settings of host vulnerability
• Aberrant LTB4 levels observed in chronic inflammation is harmful to host 
defense
• LTB4 synthesis/actions blockage restores host defense in chronic 
inflammatory diseases
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Fig. 1. Host defense mechanisms enhanced by LTB4/BLT1 axis during microbial infection
Upper panel. Upon infection, microbial recognition triggers 5-LO activation to generate 
LTB4 in phagocytes. Lower panel. LTB4 amplifies macrophage and neutrophil effector 
function by enhancing the actions of different PRRs and FcR.
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